MapLight Therapeutics

MPLT · Nasdaq · United States

Share price · MPLT

$6.65-5.17 (-43.74%) 3M

close as of 2026-11-18 · 24h delayed · vol 417K (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MPLT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+11.4%

    Nothing announced by MPLT that day or the session before.

  2. 2 Nov 2026-10.6%

    Nothing announced by MPLT that day or the session before.

  3. 29 Jul 2026+22.0%
  4. 28 Jul 2026+24.3%
  5. 27 Jul 2026-72.9%
  6. 11 May 2026+9.8%
  7. 4 May 2026-6.8%
  8. 22 Apr 2026+16.3%

    Nothing announced by MPLT that day or the session before.

  9. 9 Apr 2026+21.3%

Share of unusual movement by asset

For each asset, the share of MPLT's own-move activity since 28 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Betovumeline/fesoterodine (ML-007C-MA)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—49%
Other company news (earnings, financing, releases naming no asset)—3%
Sessions with no dated event—48%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Muscarinic M1 and M4 receptors (agonist)Small molecule
Alzheimer's DiseaseSchizophreniaAlzheimer's Disease Psychosis

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-12-03 · Fiscal period ending 2026-09-30
What to watch
2027 (1)
December 2027 (1)
Betovumeline/fesoterodine (ML-007C-MA)Phase 2Psychosis Associated With Alzheimer's Disease
Est. primary completion 2027-12 · NCT06887192 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Betovumeline/fesoterodine (ML-007C-MA)Phase 2Psychosis Associated With Alzheimer's Disease
Est. primary completion 2029-03 · NCT07459660 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Est. primary completion 2030-02 · NCT07459647 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 July 2026Topline resultML-007C-MAPhase 2 ZEPHYR of ML-007C-MA in schizophrenia met its primary endpoint
MapLight Therapeutics · Source ↗

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$53M$72M+ $233M short-term inv.$60M-$45M operating cash flowreport ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$54M$56M+ $254M short-term inv.$61M-$51M operating cash flowreport ↗
2025-Q3—$27M$64M+ $163M short-term inv.$29M-$32M operating cash flowreport ↗
2025-Q2—$27M—$30M-$34M operating cash flowreport ↗
2025-Q1—$20M—$22M-$26M operating cash flowreport ↗
2024-Q3—$17M—$19Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$138M$47M+ $258M short-term inv.$40M-$138M operating cash flowreport ↗

MapLight Therapeutics reported no revenue for 2025. R&D expense was $138.35M, up 101.9% YoY from $68.52M, and the company ended the year with $453.1M in cash, cash equivalents and investments. Full-year net loss was $161.15M, compared with $77.6M in 2024.

The company expects its cash position to fund operations through 2027. It guided to Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia reaching target enrollment of 300 patients in April 2026, with topline results expected in the third quarter of 2026; the Phase 2 IRIS trial of ML-004 for autism spectrum disorder has completed enrollment, with topline results also expected in the third quarter of 2026. FDA Fast Track designation was granted for ML-007C-MA for Alzheimer’s disease psychosis, with Phase 2 VISTA topline results expected in the second half of 2027, and the pipeline was expanded with the next-generation ML-055 M1/M4 muscarinic agonist program, with candidate nomination expected in 2026.

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$69M$38M+ $71M short-term inv.$19M-$79M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 10 purchases ($66.2M), 145 sales ($30.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-15Kroeger Christopher A. · director, Chief Executive OfficerOpen-market sale73,691$8.08$595KForm 4
2026-10-15Foff Erin Pennock · Chief Medical OfficerOpen-market sale15,355$8.08$124KForm 4
2026-10-15Hanson Kristopher · General CounselOpen-market sale9,020$8.08$73KForm 4
2026-10-15Lillie James Woodruff · Chief Scientific OfficerOpen-market sale11,513$8.08$93KForm 4
2026-10-15GILLIS JONATHAN · CAO and Interim CFOOpen-market sale10,167$8.08$82KForm 4
2026-10-15Kreitzer Anatol · Chief Discovery OfficerOpen-market sale12,248$7.84$96KForm 4
2026-09-16Hanson Kristopher · General CounselOpen-market sale16,509$11.67$193KForm 4
2026-08-17Kroeger Christopher A. · director, Chief Executive OfficerAward / grant23,145——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 81 reporting institutions held 24.8M shares ($445.0M, 58.4% of shares outstanding).

#InstitutionSharesValue
1NOVO HOLDINGS A/S3,686,622$74.9M
2FCPM III SERVICES B.V.3,226,400$65.6M
3GOLDMAN SACHS GROUP INC1,994,873$40.6M
4BlackRock, Inc.1,339,731$27.2M
5Blue Owl Capital Holdings LP1,005,929$20.5M
6Nan Fung Group Holdings Ltd971,253$19.7M
75AM Venture Management, LLC950,011$19.3M
8Sanofi912,041$18.5M
9VANGUARD CAPITAL MANAGEMENT LLC719,820$14.6M
10Pivotal bioVenture Partners Investment Advisor LLC611,447$12.4M
11Velan Capital Investment Management LP492,893$10.0M
12GEODE CAPITAL MANAGEMENT, LLC481,201$9.8M
13Siren, L.L.C.450,000$9.1M
14Vestal Point Capital, LP420,000$8.5M
15ADAR1 Capital Management, LLC374,909$7.6M